German benefit assessment hammers nail in Novartis' aliskiren coffin
This article was originally published in Scrip
Novartis' antihypertensive Rasilamlo (aliskiren plus amlopidine) offers no proven benefit over comparators, says Germany's Institute for Quality and Eficinecy in Healthcare, IWQiG. The conclusion comes as no surprise. In September the firm stopped marketing the drug in Germany because it did not have the necessary data to make a successful submission under the early benefit assessment.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.